H
Hironori Tashiro
Researcher at Kumamoto University
Publications - 60
Citations - 1357
Hironori Tashiro is an academic researcher from Kumamoto University. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 20, co-authored 56 publications receiving 1179 citations. Previous affiliations of Hironori Tashiro include RMIT University.
Papers
More filters
Journal Article
Expression of Metastasis-related nm23-H1 and nm23-H2 Genes in Ovarian Carcinomas: Correlation with Clinicopathology, EGFR, c-erbB-2, and c-erbB-3 Genes, and Sex Steroid Receptor Expression
Masaki Mandai,Ikuo Konishi,Masafumi Koshiyama,Takahide Mori,Shinji Arao,Hironori Tashiro,Hitoshi Okamura,Hiroshi Nomura,Hiroshi Hiai,Manabu Fukumoto +9 more
TL;DR: In this paper, the role of metastasis-related nm23 genes in carcinogenesis and progression of ovarian carcinoma was verified by analyzing the mRNA levels of the nm23-H1 genes of both isoforms, -H1 and -H2, together with those of the epidermal growth factor receptor, the c- erb B-2, and the c - erbB-3 genes in 45 ovarian carcinomas and 5 benign cystadenomas.
Journal Article
Expression of Multidrug Resistance Gene and Localization of P-Glycoprotein in Human Primary Ovarian Cancer
Shinji Arao,Hirofumi Suwa,Masaki Mandai,Hironori Tashiro,Kohji Miyazaki,Hitoshi Okamura,Hiroshi Nomura,Hiroshi Hiai,Manabu Fukumoto +8 more
TL;DR: Some ovarian cancer cases before chemotherapy are intrinsically multidrug resistant, which can be determined by mdr1 gene expression, and this phenotype should be taken into account for effective chemotherapy of ovarian epithelial carcinomas.
Journal ArticleDOI
c-myc over-expression in human primary ovarian tumours: Its relevance to tumour progression
TL;DR: Significant over‐ expression of the c‐myc gene at Stage III compared with other stages, and one remarkable case of over‐expression in a serous tumour of low malignant potential suggest that c‐ myc expression is temporarily activated at some stage(s) during tumorigenesis of ovarian cancer, especially of serous cancers.
Journal ArticleDOI
Neurofibromin 1 (NF1) Defects Are Common in Human Ovarian Serous Carcinomas and Co-occur with TP53 Mutations
Navneet Sangha,Rong Wu,Rork Kuick,Scott Powers,David Mu,Diane Fiander,Kit Yuen,Hidetaka Katabuchi,Hironori Tashiro,Eric R. Fearon,Kathleen R. Cho +10 more
TL;DR: The TP53 tumor-suppressor gene was mutated in all OSCs with documented NF1 mutation, suggesting that the pathways regulated by these two tumor-Suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.
Journal ArticleDOI
CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
Francisca Tjhay,Takeshi Motohara,Shingo Tayama,Dashdemberel Narantuya,Koichi Fujimoto,Jianying Guo,Isao Sakaguchi,Ritsuo Honda,Hironori Tashiro,Hidetaka Katabuchi +9 more
TL;DR: The peritoneal disseminated metastasis of epithelial ovarian cancer is initiated by the CD44v6‐positive subpopulation, and CD 44v6 expression is a biomarker for the clinical outcome of advanced ovarian cancer patients.